Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 1 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 12419963

    Diels-Alder conjugation methods

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  2. US 12421317

    Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  3. US 12421315

    CLL-1 targeted immunotherapies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  4. US 12421512

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 23, 2025 · Expires Sep 18, 2045

    granted
  5. US 12415856

    EGFR x CD28 multispecific antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  6. US 12410442

    Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  7. US 12402611

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  8. US 12404505

    Delivery of a gene-editing system with a single retroviral particle and methods of generation and use

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 2, 2025 · Expires Aug 28, 2045

    granted
  9. US 12396444

    Mouse comprising a humanized TRKB locus

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  10. US 12397028

    Adoptive cellular therapy

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  11. US 12396952

    Tuning of release kinetics in hydrogels

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  12. US 12398212

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 26, 2025 · Expires Aug 21, 2045

    granted
  13. US 12391753

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  14. US 12389889

    Mouse having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  15. US 12391920

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  16. US 12391734

    PD-1 homing endonuclease variants, compositions, and methods of use

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 19, 2025 · Expires Aug 14, 2045

    granted
  17. US 12378557

    Treatment of sepsis with PCSK9 and LDLR modulators

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  18. US 12377159

    Steroids and protein-conjugates thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  19. US 12378258

    Biologically active molecules, conjugates thereof, and therapeutic uses

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  20. US 12370257

    Materials and methods of treating MHC-I-opathy risk haplotypes

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  21. US 12371503

    Methods of treatment using a leptin receptor agonist antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  22. US 12365711

    TGFβ signal convertor

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  23. US 12350318

    Combination therapy to treat brain cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  24. US 12350374

    Fabrication of protein-encapsulating microgels

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted